Michel Demeule
Geen lopende functies
Profiel
Michel Demeule is currently a Director at Katana Biopharma, Inc. He previously worked as a Research Director at Angiochem, Inc. and as a Researcher at the University of Quebec.
Dr. Demeule earned a doctorate degree from the University of Montréal in 1992.
Eerdere bekende functies van Michel Demeule
| Bedrijven | Functie | Einde |
|---|---|---|
| University of Quebec | Corporate Officer/Principal | - |
Katana Biopharma, Inc.
 Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Directeur/Bestuurslid | - |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Michel Demeule
| University of Montréal | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Katana Biopharma, Inc.
Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Health Services |
